CSTL CASTLE BIOSCIENCES INC

CIK 0001447362 18 ready 8-Ks latest May 6, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 18

Latest filing May 29, 2026, 4:14 PM ET

Top materiality 0.85

Event mix earnings ×13 · other_material ×3 · other ×2

Sentiment 11 pos · 1 neg · 6 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for CSTL

Highest-materiality recent filing

Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M

August 5, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.
Total test reports 25,102 (+49% YoY); TissueCypher +230%, DecisionDx-SCC +60%.

Read filing →

May 6, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences Q1 revenue $83.7M; core tests +36%; raises FY guidance to $345-355M

Revenue $83.7M vs $88.0M Q1 2025; core test reports +36% YoY (DecisionDx-Melanoma +16%, TissueCypher +58%).
February 26, 2026, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Castle Biosciences FY2025 revenue up 4% to $344M, net loss of $24.2M vs income of $18.2M in 2024

FY2025 revenue $344.2M (+4% YoY); excluding discontinued tests growth 34%. Core test reports (DecisionDx-Melanoma, TissueCypher) +37%.
January 13, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Biosciences expects 2025 revenue >$340M, above guidance; core test volumes up 37% YoY

2025 total revenue >$340M, above guided range of $327-335M.
November 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q3 revenue $83M, raises FY2025 guidance to $327-335M; launches AdvanceAD-Tx test

Revenue $83.0M (Q3 2025) vs $85.8M YoY; net loss $0.5M vs net income $2.3M.
August 4, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q2 revenue $86.2M, raises FY2025 guidance; core test volumes up 33% YoY

Q2 revenue $86.2M (vs $87.0M); adjusted revenue $86.2M. Core tests (DecisionDx-Melanoma, TissueCypher) volumes up 33% YoY.
May 5, 2025, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 7.01 item 9.01

Castle Q1 revenue $88M (+21% YoY), raises FY guidance to $287-297M, acquires Previse

Q1 revenue $88.0M (+21% YoY); total test reports 24,402 (+17%); core driver reports +33% YoY.
February 27, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences FY 2024 revenue up 51% to $332M, net income $18.2M vs loss; 2025 outlook $280-295M

Full-year 2024 revenue $332.1M (+51% YoY); test reports 96,071 (+36% YoY).
January 13, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01

Castle Biosciences expects 2024 revenue at least $330M (≥50% growth); Medicare non-covers DecisionDx-SCC

Full-year 2024 revenue expected to meet or exceed top of guidance range $320-330M, at least 50% growth over 2023.
November 4, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q3 revenue up 39% to $85.8M; raises FY2024 guidance to $320-330M

Revenue $85.8M (+39% YoY); net income $2.3M vs. ($6.9M) loss; adj. EBITDA $21.6M vs $6.6M.
August 5, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M

Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.
May 2, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences Q1 revenue $73M (+74% YoY); raises FY2024 guidance to $255-265M

Q1 revenue $73.0M (+74% YoY); adjusted revenue $71.3M (+64% YoY).
February 28, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences FY2023 revenue $219.8M (+60%); Q4 $66.1M; guides 2024 $235-240M

Full-year 2023 revenue $219.8M (+60% YoY); total test reports 70,429 (+59%). Q4 revenue $66.1M (+72% YoY).
January 8, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences expects 2023 revenue >$210M, exceeding guidance; test volume +59%

Expects 2023 total revenue >$210M, at least 53% growth over 2022, surpassing prior guidance floor of $200M.

Executive changes

Departed

Mara G. Aspinall

Director

CSTL · CASTLE BIOSCIENCES INC

Filed: March 27, 2024, 7:59 PM ET

On March 26, 2024, Mara G. Aspinall notified the Company that she will not to stand for re-election to the board of directors (the “Board”) of the Company at the expiration of her current term at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).

Appointed

Rodney Cotton

Class II Director

CSTL · CASTLE BIOSCIENCES INC

Effective: 2024-03-26
Filed: March 27, 2024, 7:59 PM ET

On March 26, 2024, following the recommendation of the nominating and corporate governance committee of the Board, the Board increased the size of the Board from eight to nine members and appointed Rodney Cotton to serve as a Class II director with a term ending at the 2024 Annual Meeting.

Earnings & guidance

2026-Q1 EPS reported -$0.49 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

11 positive 1 negative 6 neutral

source · CSTL on sec.gov